HRP20020057A2 - 1,4,5,6-tetrahydropyrimidine derivative as a vitronectin inhibitor - Google Patents

1,4,5,6-tetrahydropyrimidine derivative as a vitronectin inhibitor Download PDF

Info

Publication number
HRP20020057A2
HRP20020057A2 HR20020057A HRP20020057A HRP20020057A2 HR P20020057 A2 HRP20020057 A2 HR P20020057A2 HR 20020057 A HR20020057 A HR 20020057A HR P20020057 A HRP20020057 A HR P20020057A HR P20020057 A2 HRP20020057 A2 HR P20020057A2
Authority
HR
Croatia
Prior art keywords
formula
compound
ethyl
acid
ylcarbamoyl
Prior art date
Application number
HR20020057A
Other languages
English (en)
Croatian (hr)
Inventor
Gerhard Breipohl
Peyman Anuschirwan
Theodor Wollmann
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of HRP20020057A2 publication Critical patent/HRP20020057A2/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/12—Nitrogen atoms not forming part of a nitro radical
    • C07D239/16—Nitrogen atoms not forming part of a nitro radical acylated on said nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HR20020057A 1999-07-21 2000-07-08 1,4,5,6-tetrahydropyrimidine derivative as a vitronectin inhibitor HRP20020057A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99114372A EP1070707A1 (en) 1999-07-21 1999-07-21 1,4,5,6-tetrahydropyrimidine derivative as a vitronectin inhibitor
PCT/EP2000/006504 WO2001007417A1 (en) 1999-07-21 2000-07-08 1,4,5,6-tetrahydropyrimidine derivative as a vitronectin inhibitor

Publications (1)

Publication Number Publication Date
HRP20020057A2 true HRP20020057A2 (en) 2003-06-30

Family

ID=8238643

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20020057A HRP20020057A2 (en) 1999-07-21 2000-07-08 1,4,5,6-tetrahydropyrimidine derivative as a vitronectin inhibitor

Country Status (29)

Country Link
US (1) US6900318B1 (cs)
EP (2) EP1070707A1 (cs)
JP (1) JP2003505450A (cs)
KR (1) KR20020063838A (cs)
CN (1) CN1361767A (cs)
AR (1) AR024794A1 (cs)
AT (1) ATE286030T1 (cs)
AU (1) AU775567B2 (cs)
BG (1) BG106322A (cs)
BR (1) BR0012554A (cs)
CA (1) CA2379086C (cs)
CZ (1) CZ200285A3 (cs)
DE (1) DE60017150D1 (cs)
EA (1) EA200200187A1 (cs)
EE (1) EE200200031A (cs)
HK (1) HK1048316A1 (cs)
HR (1) HRP20020057A2 (cs)
HU (1) HUP0201939A3 (cs)
IL (1) IL147396A0 (cs)
MX (1) MXPA02000674A (cs)
MY (1) MY133525A (cs)
NO (1) NO20020311D0 (cs)
NZ (1) NZ516233A (cs)
PL (1) PL353014A1 (cs)
SK (1) SK522002A3 (cs)
TR (1) TR200200116T2 (cs)
WO (1) WO2001007417A1 (cs)
YU (1) YU90201A (cs)
ZA (1) ZA200110361B (cs)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10501222A (ja) * 1994-05-27 1998-02-03 メルク エンド カンパニー インコーポレーテッド 破骨細胞仲介骨吸収を抑制するための化合物
EP0933367A1 (en) * 1997-12-19 1999-08-04 Hoechst Marion Roussel Deutschland GmbH Novel acylguanidine derivates as inhibitors of bone resorption and as vitronectin receptor antagonists
IL137423A0 (en) * 1998-01-23 2001-07-24 Aventis Pharma Gmbh Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion
US6313119B1 (en) * 1998-01-23 2001-11-06 Adventis Pharma Deutschland Gmbh Sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion

Also Published As

Publication number Publication date
AR024794A1 (es) 2002-10-23
HUP0201939A2 (hu) 2002-12-28
CN1361767A (zh) 2002-07-31
IL147396A0 (en) 2002-08-14
KR20020063838A (ko) 2002-08-05
DE60017150D1 (de) 2005-02-03
AU6822600A (en) 2001-02-13
ATE286030T1 (de) 2005-01-15
TR200200116T2 (tr) 2002-04-22
BR0012554A (pt) 2002-04-16
NO20020311L (no) 2002-01-21
SK522002A3 (en) 2003-05-02
WO2001007417A1 (en) 2001-02-01
EE200200031A (et) 2003-02-17
HUP0201939A3 (en) 2003-02-28
CA2379086A1 (en) 2001-02-01
MXPA02000674A (es) 2002-07-30
NO20020311D0 (no) 2002-01-21
EA200200187A1 (ru) 2002-10-31
ZA200110361B (en) 2002-12-18
YU90201A (sh) 2004-07-15
NZ516233A (en) 2004-07-30
HK1048316A1 (zh) 2003-03-28
US6900318B1 (en) 2005-05-31
AU775567B2 (en) 2004-08-05
EP1204646A1 (en) 2002-05-15
MY133525A (en) 2007-11-30
EP1070707A1 (en) 2001-01-24
CZ200285A3 (cs) 2003-02-12
PL353014A1 (en) 2003-10-06
BG106322A (en) 2002-08-30
JP2003505450A (ja) 2003-02-12
EP1204646B1 (en) 2004-12-29
CA2379086C (en) 2009-01-06

Similar Documents

Publication Publication Date Title
KR20010033281A (ko) 골흡수 억제제 및 비트로넥틴 수용체 길항제인 신규 아실구아니딘 유도체
JPH07188165A (ja) ５，６−双環性グリコプロテインＩＩｂ／ＩＩＩａ拮抗剤
US5565464A (en) Compounds having angiotensine II antagonistic activity
NO311083B1 (no) Nye cykloalkylderivater, fremgangsmåte for fremstilling derav, farmasöytiske preparater inneholdende forbindelsene samtanvendelse av forbindelsene
JP2002501054A (ja) 骨吸収の阻害剤として及び細胞接着の阻害剤としての新規のスルホンアミド誘導体
US7763621B2 (en) Vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same
HRP20020057A2 (en) 1,4,5,6-tetrahydropyrimidine derivative as a vitronectin inhibitor
US6867213B2 (en) (2S)-2-(adamantan-1-ylmethoxycarbonylamino)-3-(4-(2-(1,4,5,6-tetrhydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propionic acid isopropyl ester, its preparation and its use
JP2003532732A (ja) ビトロネクチン受容体の新規な拮抗薬誘導体
JP2002530384A (ja) 新規なアシルグアニジン誘導体、それらの製造方法、薬剤としてのそれらの使用及びそれらを含有する製薬組成物
US6495545B1 (en) 1,4-benzodiazepinone derivatives and their use as integrin antagonists
US6391904B1 (en) Iminoguanidine derivatives, preparation method, use as medicines
JP2002530403A (ja) 新規のベンゾフラン誘導体、それらの製造方法及び薬剤としてのそれらの使用
JP2002541256A (ja) 新規エンドセリン転換酵素阻害剤、その製造および使用

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
OBST Application withdrawn